FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
Shares of drug manufacturer Catalent (NYSE: CTLT) declined Friday morning after telling investors it will provide a business update today instead of a normal review of its third quarter results. This was the third time Catalent delayed the earnings release, once again citing problems with accounting adjustments.
Catalent... More
Catalent (NYSE: CTLT) Sees FY23 Revenue of $4.25B to $4.35B vs Consensus $4.44B (Prior $4.625B -$4.875B)
Adjust EBITDA $725M to $775MAdj. Net Income $187M to $228M
